Short interest in Gilead Sciences Inc (NASDAQ:GILD) decreased during the last reporting period, falling from 22.34M to 21.39M. This put 1.72% of the company's publicly available shares short.

Intel, Core BTS, Salesforce, Verizon, ServiceNow, Cisco and Cyderes were among the tech companies making key executive hires ...

If you're hunting for the best day hike in Washington, I recommend heading to Tuck and Robin Lakes near Skykomish. Nestled in the Alpine Lakes Wilderness, this challenging route is either a one-day ...

Shares of Gilead Sciences Inc. GILD advanced 2.00% to $105.25 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to ...

In the latest trading session, Gilead Sciences (GILD) closed at $105.25, marking a +2% move from the previous day. The stock lagged the S&P 500's daily gain of 9.52%. Elsewhere, the Dow saw an ...

“It’s been more than five years and I’m getting the help I need thanks to my doctor.” Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes ...

Gilead Sciences (GILD), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This HIV and hepatitis C drugmaker has seen a nice streak of ...

In its first quarter 2025 investor letter, ClearBridge Value Strategy emphasized stocks such as Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company.

AbbVie and Gilead Sciences are leading drugmakers in immunology and HIV, respectively. Both companies have excellent lineups and pipelines that should lead to strong results. Income-oriented ...